cFGF23 specific antibodies and their use in the preparation of auxiliary diagnostic reagents for osteoporosis
By providing a monoclonal antibody that specifically binds to the cFGF23 protein, different segments of the FGF23 protein are identified, solving the problem of insufficient detection sensitivity in existing technologies and achieving highly sensitive cFGF23 detection, which is suitable for the auxiliary diagnosis of osteoporosis.
CN119874901BActive Publication Date: 2026-07-24SHANGHAI LIANGRUN BIOMEDICINE TECH CO LTD
1 Cites 0 Cited by
Patent Information
- Application Number
- CN202411993818.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-31
- Publication Date
- 2026-07-24
- Estimated Expiration
- 2044-12-31
AI Technical Summary
Technical Problem
The existing technology for cFGF23 detection suffers from insufficient sensitivity, mainly due to the short C-terminal fragment of FGF23, which results in a limited number of paired antibodies and severe spatial conformational competition in the detection system.
Method used
We provide a monoclonal antibody that specifically binds to the cFGF23 protein, recognizing different segments of the FGF23 protein, including segments 180-205, 200-229, and 222-251, for high-sensitivity detection using a chemiluminescent immunoassay kit.
Benefits of technology
The detection sensitivity and specificity of cFGF23 were improved, with a detection limit of 6.25 pg/ml, making it suitable for the auxiliary diagnosis of osteoporosis. The specificity was 88.2% and the sensitivity was 69.4%.
✦ Generated by Eureka AI based on patent content.
Abstract
The present application relates to cFGF23 specific antibodies and their use in the preparation of osteoporosis auxiliary diagnostic reagents, and belongs to the technical field of disease auxiliary diagnosis. The three specific antibodies in the present application can specifically recognize the C-terminal of FGF23 eukaryotic protein, and two capture antibodies and one detection antibody respectively recognize the C-terminal (180-205), C-terminal (200-229) and C-terminal (222-251) of FGF23 protein. When detecting cFGF23 protein, the mixed capture of the two capture antibodies can greatly improve the capture performance of the detection system for cFGF23.
Need to check novelty before this filing date? Find Prior Art